Germany Exhibition Health (000813): Intends To Increase Capital To Beijing Oriental

　　德展健康(000813.SZ)公布，公司為進一步加快在大健康領域的技術研發和應用，通過投資驅動加速大健康產業鏈的布局，公司與北京東方略生物醫藥科技股份有限公司(“北京東方略”、“標的公司”)及其原股東(上海仟德股權投資合伙企業(有限合伙)、仇思念、世耀生物醫藥技術(上海)有限公司、嘉興星空倍益投資合伙企業(有限合伙)、陳明鍵、深圳市熔巖奕新投資合伙企業(有限合伙)、楊維平、達孜東方高圣夏雨資本管理有限公司、上海展高股權投資合伙企業(有限合伙)、張馳、融智開普創業投資(北京)有限公司)經友好協商于2019年12月16日在北京市朝陽區共同簽署了《北京東方略生物醫藥科技股份有限公司增資協議》(“增資協議”)，公司擬對北京東方略進行增資，公司根據增資協議的條款和條件以其合法擁有的現金出資3億元認購標的公司此次新增3615萬股股份，超 The amount of newly registered capital is 263 million 850 thousand yuan, which is included in the capital reserve of the target company. Beijing Eastern slightly unanimously agreed that the registered capital of Beijing orient slightly increased from 119 million 530 thousand yuan to 155 million 680 thousand yuan.

Beijing Oriental bio pharmaceutical Polytron Technologies Inc business scope: Sales of medical devices category III; retail drugs; medical research and testing development; natural science research and test development: technology development, technology transfer, technology consulting, technical services; technology import and export, import and export of goods, agents import and export; sales of medical devices category I and II. (enterprises choose their own business projects according to law and carry out their business activities: the projects that are approved according to law must be approved by the relevant departments and carry out business activities in accordance with the approved contents; they shall not be allowed to engage in any business activities prohibited or restricted by industrial policies in this Municipality. )

Orient is a biopharmaceutical company focusing on the clinical development and commercialization of cancer innovative drugs. Its important variety is the exclusive licensing of patents and know-how in the Greater China region (mainland China, Taiwan, Hongkong and Macao) for the DNA therapeutic vaccine targeting HPV cervical cancer precancerous lesions. In addition, there are a number of products in pre clinical / clinical stages. VGX-3100 is mainly used for the treatment of cervical cancer precancerous lesions caused by HPV16 and HPV18 virus infection. It is necessary to change the status quo of cervical cancer precancerous lesions, mainly rely on cervical conization and hysterectomy, and reduce the risk of recurrence. At the same time, the elimination of HPV virus and the prevention of cervical cancer can further reduce the incidence of cervical cancer. The product has huge potential market in China. This transaction can help Germany to enrich its own product line and expand its market. For the company's continuous layout in the field of cancer, improve the company's industry influence and comprehensive competitiveness, in line with the company's long-term development strategy.

The transaction price is determined by reference value and negotiated price is fair, and there is no damage to the interests of the company and shareholders. The foreign investment project is expected to have no substantial impact on the health performance of Germany exhibition in the near future, and will become a new profit growth point in the future.